Page 204 - Functional impairment and cues for rehabilitation of head and neck cancer patients -

202
Chapter 8
REFERENCES
1. Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014;11(3):177-80.
2. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018.
3. Rier HN, Jager A, Sleijfer S, Maier AB, Levin MD. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the
Literature. Oncologist. 2016;21(11):1396-409.
4. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic
review. Eur J Cancer. 2016;57:58-67.
5. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from
colorectal cancer resection surgery. Br J Cancer. 2012;107(6):931-6.
6. Smith AB, Deal AM, Yu H, et al. Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol. 2014;191(6):1714-20.
7. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast
cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920-6.
8. Cushen SJ, Power DG, Teo MY, et al. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma
Treated With Sunitinib. American journal of clinical oncology. 2017;40(1):47-52.
9. Grossberg AJ, Chamchod S, Fuller CD, et al. Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head
and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016;2(6):782-9.
10. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with
locally advanced head and neck cancer. Oral Oncol. 2017;71:26-33.
11. Kabarriti R, Bontempo A, Romano M, et al. The impact of dietary regimen compliance on outcomes for HNSCC patients treated with radiation
therapy. Support Care Cancer. 2018;26(9):3307-13.
12. Nishikawa D, Hanai N, Suzuki H, et al.The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma. ORL J Otorhinolaryngol
Relat Spec. 2018;80(1):1-9.
13. Sato S, Kunisaki C, Suematsu H, et al. Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving
Chemoradiotherapy. In Vivo. 2018;32(3):603-10.
14. Tamaki A, Manzoor NF, Babajanian E, et al. Clinical Significance of Sarcopenia among Patients with Advanced Oropharyngeal Cancer. Otolaryngol
Head Neck Surg. 2018:194599818793857.
15. Bril SI, Pezier TF, Tijink BM, et al. Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival
in patients undergoing total laryngectomy. Head Neck. 2019.
16. Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: patients’perspectives. Otolaryngol Head Neck
Surg. 2011;145(5):767-71.
17. Kierkels RGJ, Wopken K, Visser R, et al. Multivariable normal tissue complication probability model-based treatment plan optimization for grade
2-4 dysphagia and tube feeding dependence in head and neck radiotherapy. Radiotherapy and oncology : journal of the European Society for
Therapeutic Radiology and Oncology. 2016;121(3):374-80.
18. Nevens D, Deschuymer S, Langendijk JA, et al. Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional
and a partially accelerated radiotherapy scheme. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and
Oncology. 2016;118(2):293-7.
19. Wopken K, Bijl HP, Langendijk JA. Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer:
A systematic review of literature. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
2018;126(1):56-67.
20. Brown TE, Crombie J, Spurgin AL, et al. Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in
patients with head and neck cancer. Head & neck. 2016;38 Suppl 1:E1163-71.
21. van der Linden NC, Kok A, Leermakers-Vermeer MJ, et al. Indicators for Enteral Nutrition Use and Prophylactic Percutaneous Endoscopic
Gastrostomy Placement in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy. Nutrition in clinical practice : official publication
of the American Society for Parenteral and Enteral Nutrition. 2017;32(2):225-32.
22. Brown TE, Spurgin AL, Ross L, et al. Validated swallowing and nutrition guidelines for patients with head and neck cancer: identification of high-
risk patients for proactive gastrostomy. Head & neck. 2013;35(10):1385-91.
23. Karsten RT, Stuiver MM, van der Molen L, et al. From reactive to proactive tube feeding during chemoradiotherapy for head and neck cancer: A
clinical prediction model-based approach. Oral Oncol. 2018;88:172-9.
24. Yang W, McNutt TR, Dudley SA, et al. Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use
in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of
Gabapentin. Dysphagia. 2016;31(2):206-13.
25. Nugent B, Parker MJ, McIntyre IA. Nasogastric tube feeding and percutaneous endoscopic gastrostomy tube feeding in patients with head and neck
cancer. J Hum Nutr Diet. 2010;23(3):277-84.
26. Clavel S, Fortin B, Despres P, et al. Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach. Int J Radiat Oncol Biol Phys. 2011;79(3):763-9.